Market Place
Sourcing Support
AiCuris Achieves Milestones In Anti-viral Solutions For At-Risk Patients
17 Jul 2024 //
BUSINESSWIRE
Health Canada approves new indication for Merck’s Prevymis
22 Apr 2024 //
PHARMABIZ
Merck Receives Positive EU CHMP Opinion for PREVYMIS
17 Oct 2023 //
BUSINESSWIRE
Merck`s CMV drug is approved for kidney transplant patients
07 Jun 2023 //
ENDPTS
U.S. FDA Approves New Indication for Merck’s PREVYMIS for Prevention of CMV
06 Jun 2023 //
BUSINESSWIRE
U.S. FDA Accepts for Priority Review the Supplemental NDA for Merck’s PREVYMIS
17 Feb 2023 //
BUSINESSWIRE
Merck`s Prevymis outdoes Roche`s Valcyte in toxicity measure
25 Oct 2022 //
FIERCEPHARMA
NICE recommendation for MSD’s Prevymis after re-evaluation
03 Jun 2019 //
PHARMATIMES
Merck antiviral drug Prevymis wins NICE over
30 May 2019 //
FIERCE PHARMA
Prescription med: registration of new chemical entities in Australia
09 Jul 2018 //
TGA
Merck Sharp & Dohme`s Prevymis (letermovir) Receives Approval In Europe
19 Jan 2018 //
EMA
New England Journal of Medicine Publishes Phase 3 Clinical Study of PREVYMIS™
07 Dec 2017 //
BUSINESSWIRE
Merck Receives Positive CHMP Opinion for PREVYMIS (letermovir) in the EU Union
13 Nov 2017 //
BIOSPACE
MSD’s Prevymis approved for CMV prevention
13 Nov 2017 //
PHARMA TIMES
Ten medicines recommended for approval, including two orphan
11 Nov 2017 //
EMA
Merck`s new CMV med Prevymis set for launch at $19K-plus
10 Nov 2017 //
FIERCE PHARMA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.